Loading
Led DECISION, the trial that made sorafenib the first approved targeted drug for radioiodine-refractory thyroid cancer.
Marcia Brose was principal investigator of DECISION, the phase 3 trial that showed sorafenib doubles progression-free survival in radioiodine-refractory differentiated thyroid cancer and became the first targeted therapy approved for the disease in 40 years. She has led cabozantinib (COSMIC-311) and RET-inhibitor trials in thyroid cancer and chairs medical oncology at Jefferson.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tags thyroid, targeted-therapy.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer and the tag thyroid.
Shares Thyroid cancer and the tag thyroid.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/